Quick Answer
Neuphoria Therapeutics Inc. reported Total Assets of $28.59 million for the year ending 2025.
- Neuphoria Therapeutics Inc. showed an increase of +3.4% in Total Assets from 2024 to 2025.
- This data is from Neuphoria Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2024: $22.92 million | Q4 2024: $18.17 million | Q1 2025: $30.71 million | Q2 2025: $28.59 million | Q3 2025: $27.34 million | Q4 2025: $36.60 million.
- Over the full 5 years of available data (2021 to 2025), Neuphoria Therapeutics Inc.'s Total Assets has declined by 47.3%.
- Historical annual values: Fiscal year 2025: $28.59 million | Fiscal year 2024: $27.65 million | Fiscal year 2023: $28.56 million | Fiscal year 2022: $65.31 million | Fiscal year 2021: $54.26 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: